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ABSTRACT
Introduction Remote ischaemic preconditioning 
(RIPC) using a non- invasive pneumatic tourniquet is a 
potential method for reducing ischaemia- reperfusion 
injury. RIPC has been extensively studied in animal 
models and cardiac surgery, but scarcely in solid organ 
transplantation. RIPC could be an inexpensive and simple 
method to improve function of transplanted organs. 
Accordingly, we aim to study whether RIPC performed in 
brain- dead organ donors improves function and longevity 
of transplanted organs.
Methods and analyses RIPTRANS is a multicentre, 
sham- controlled, parallel group, randomised superiority 
trial comparing RIPC intervention versus sham- intervention 
in brain- dead organ donors scheduled to donate at 
least one kidney. Recipients of the organs (kidney, liver, 
pancreas, heart, lungs) from a randomised donor will 
be included provided that they give written informed 
consent. The RIPC intervention is performed by inflating 
a thigh tourniquet to 300 mm Hg 4 times for 5 min. 
The intervention is done two times: first right after the 
declaration of brain death and second immediately before 
transferring the donor to the operating theatre. The 
sham group receives the tourniquet, but it is not inflated. 
The primary endpoint is delayed graft function (DGF) in 
kidney allografts. Secondary endpoints include short- term 
functional outcomes of transplanted organs, rejections and 
graft survival in various time points up to 20 years. We aim 
to show that RIPC reduces the incidence of DGF from 25% 
to 15%. According to this, the sample size is set to 500 
kidney transplant recipients.
Ethics and dissemination This study has been approved 
by Helsinki University Hospital Ethics Committee and 
Helsinki University Hospital’s Institutional Review Board. 
The study protocol was be presented at the European 
Society of Organ Transplantation congress in Copenhagen 
14−15 September 2019. The study results will be 
submitted to an international peer- reviewed scientific 
journal for publication.
Trial registration number NCT03855722.
INTRODUCTION
Solid organ transplantation is an established 
standard of care for end- stage dysfunction 
of different organs, but the availability of 
the treatment is greatly limited globally by 
the shortage of organ donors. On the other 
hand, the lifetime of a transplanted organ 
is often limited and there is a number of 
patients waiting for a second or subsequent 
transplant.1–6 A transplanted organ is exposed 
to ischaemia- reperfusion injury during the 
transplantation process.7 Alleviating this 
injury could improve the function and life-
time of transplanted organs.
Remote ischaemic preconditioning (RIPC) 
is an old concept where remotely produced 
ischaemia induces protective changes in 
distant organs or tissues and renders them 
less susceptible for future ischaemia via 
Strengths and limitations of this study
 ► The study method, a multicentre, double- blinded, 
sham- controlled, randomised superiority trial, is the 
best available method to investigate the effects of 
remote ischaemic preconditioning (RIPC) performed 
in the donor on the function and longevity of trans-
planted organs in the recipient.
 ► RIPC is an extremely simple, reproducible and inex-
pensive method.
 ► The sample size, 500 kidney transplant recipients, is 
large enough to provide confidence in the estimates 
of outcomes.
 ► Primary outcome, delayed graft function of kidney 
allograft, is clinically highly relevant, easy to mea-
sure and objective.
 ► As the sample size is calculated for kidney trans-
plantation, outcomes of other organ recipients might 
be underpowered.
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hormonal, metabolic and neuronal mechanisms.8 As 
an intervention, RIPC is easy and cheap to perform—
an inflatable tourniquet is used to occlude upper or 
lower limb. RIPC has been extensively studied in animal 
models,9–11 and in human clinical trials of cardiac surgery. 
The largest of these clinical trials—RIPHeart,12 ERICCA13 
and CONDI-2/ERIC- PPCI14—have not been successful 
to show benefit from RIPC, but this might be due to the 
fact that the patients suffering from chronic myocardial 
ischaemia already have maximal compensatory mecha-
nisms in use. This could also partially explain the results 
of RenalRIP trial, in which RIPC reduced acute kidney 
injury associated with cardiac surgery without affecting 
cardiac parameters.15
One of the postulated reasons for negative results in 
RIPHeart and ERICCA trials is the use of propofol instead 
of the volatile anaesthetics, even though this has not been 
fully verified.16 In the donation after brain death (DBD) 
transplantation setting, when the RIPC intervention is 
done to a brain dead donor, propofol is not used and 
should not prevent the effect of RIPC. Propofol may be 
used in the recipient surgery, but there is at least prelim-
inary small animal data, that this may not prevent effec-
tiveness of RIPC.17
Organ transplantation is a lucrative field to study RIPC, 
as the donor organs are healthy, and do not suffer from 
chronic ischaemia, but face invariable acute ischaemia 
of various durations. RIPC has been studied little in clin-
ical transplantation and results have been controversial. 
An RIPC intervention done to heart transplant recipi-
ents together with post conditioning 20 min after aortic 
declamping reduced cTnI levels at 6 hours after trans-
plantation.18 In a recent trial RIPC done to living liver 
donors reduced postoperative aspartate aminotransferase 
levels in liver recipients,19 whereas a pilot study of the 
RIPCOLT trial with RIPC done on liver transplant recipi-
ents demonstrated no short- term benefits.20
Direct ischaemic preconditioning with clamping of 
liver hilum in DBD was not was not beneficial and could 
even induce excessive ischaemic damage.21 A retrospec-
tive post hoc analysis of two such trials showed that liver 
ischaemic conditioning had no RIPC effect for kidneys.22 
The liver- RIPC may provide an insufficient stimulus for 
the kidneys and the authors speculated that limb isch-
aemia could be a better method for RIPC. In a study of 
29 kidney transplant patients RIPC done on DBD donors 
resulted in lower creatinine levels at 15 and 30 days after 
transplantation, but the change in glomerular filtration 
rate did not reach statistical significance.23 As far as we 
know, no larger randomised controlled trial with limb- 
RIPC on DBD donors have been published.
A small study with 20 living donor kidney recipients per 
group found no difference in kidney function whether 
RIPC was done on donor or recipient.24 A larger trial 
of 170 living kidney donor—recipient pairs with RIPC 
done on donors reported lower postoperative creatinine 
values on donors after RIPC but no long- term benefits for 
donors or recipients.25
The largest kidney transplant RIPC trial to date, the 
REPAIR trial, showed that a RIPC performed in both 
donor and recipient immediately before a living- donor 
kidney surgery improved the estimated glomerular filtra-
tion for the whole follow- up period of 5 years.26 27 The 
kidney allografts from living donors are subjected to 
very short ischaemia (in Finland this is typically less than 
2 hours) and even greater benefits could be obtained 
if RIPC is performed in deceased donors, where isch-
aemia times are much longer (median 15 hours for 
kidney allografts in Finland, even longer in other coun-
tries). RIPC intervention performed to the recipients 
of deceased donor kidneys during the transplantation 
surgery did not improve kidney function in CONTEXT 
trial.26 This study can be criticised for performing RIPC 
in the recipients instead of donors, because the ischaemic 
injury has already taken place before RIPC.
The aim of this study is to show that RIPC performed in 
brain- dead donors (DBD) can be used to improve func-
tion and longevity of transplanted organs.
METHODS AND ANALYSIS
Study design
The RIPTRANS trial is a multicentre, double- blinded, 
parallel group, individual donor randomised superiority 
trial comparing RIPC with a sham- procedure performed 
in brain- dead donors. There is only one transplanta-
tion centre (Helsinki University Hospital) in Finland 
that covers the whole country and procurement team 
travels to all donor hospitals in Finland. This protocol 
was drafted in accordance with the Standard Protocol 
Items: Recommendations for Interventional Trials state-
ment.27 Amendments made to the protocol can be found 
in supplemental (online supplemental file 1).This trial is 
registered in  ClinicalTrials. gov, the first registration date 
was 27 February 2019.
Participants
RIPC or sham procedure will be performed on a brain- 
dead donor fulfilling inclusion and exclusion criteria. All 
brain- dead donors in participating hospitals scheduled 
for at least one kidney procurement will be included. 
Donors with significant haemodynamic instability 
(assessed by the intensive care physician responsible for 
the treatment of the donor) and under the age of 18 
years will be excluded. Donors (or potential recipients of 
organ from this donor), who are participating in a trial 
with conflicting interventions or outcomes, will also be 
excluded. Although the donors are randomised and the 
intervention is carried out in donors, the recipients are 
the actual participants of this trial. All patients receiving 
a kidney, liver, combined pancreas- kidney, heart or lungs 
from a donor randomised in the trial will be included 
in the trial provided that they give a written informed 
consent (see online supplemental file 2) to participate 
in the trial and are at least 18 years old. The informed 
consent will be presented to the patient by a study nurse 









pen: first published as 10.1136/bm






3Uutela A, et al. BMJ Open 2020;10:e038340. doi:10.1136/bmjopen-2020-038340
Open access
or physician. As based on the previous studies, RIPC is 
supposedly not harmful for the donor, and the lack of 
consent from any of the transplant recipients does not 
exclude the donor from the study, nor the possible inclu-
sion of the other recipients. There are no other exclu-
sion criteria for recipients who receive above- mentioned 
organs from a randomised donor.
Randomisation and masking
Eligible donors will be randomly allocated in a 1:1 ratio 
to either RIPC or sham- procedure group. The randomis-
ation sequence was generated using a web- based commer-
cial service (Sealed Envelope) with randomly variable 
block size (4, 6 or 8) and stratified according to donor 
age (under/over 60 years of age), planned organ to be 
procured (kidneys only/abdominal organs only/both 
thoracic and abdominal organs) and donor cardiopul-
monary resuscitation (yes/no). The randomisation and 
allocation to either RIPC or sham- intervention is done 
by a transplant coordinator, who is not blinded to the 
allocated treatment, using the same web- based service. 
Once the donor is allocated, the transplant coordinator 
sends electronically or via fax written instructions on how 
to perform the allocated treatment to the intensive care 
team responsible for the treatment of the donor, who also 
are not blinded to the treatment. This intensive care team 
will collect data regarding the actual timing of the allo-
cated procedure and whether this caused any noticeable 
changes in the donor hemodynamics. All researchers 
and all other treating personnel are blinded, such as 
procuring surgeons, transplant surgeons, treating physi-
cians, data collectors and data analysts as well as recipi-
ents. After the trial recruitment has been closed and data 
collected, the allocated group will be named as A and B 
before the data are analysed. Once the data analyses for 
primary and secondary outcomes are completed, the full 
blinding will be removed. No emergency unblinding is 
planned, but incidents of possible breaches in blinding 
will be recorded.
Procedures
RIPC will be performed as follows: donor’s thigh will 
be occluded 4 times for 5 min using tourniquet inflated 
to 300 mm Hg each followed by 5 min of deflation. The 
intervention will be performed two times (once in both 
thighs). Once as soon as possible after brain death is deter-
mined, and once right before transferring the donor to 
the operation room for procurement. Sham- intervention 
will be performed by putting the inflatable tourniquet in 
place similarly, but not inflating it. Apart from the RIPC 
or sham- intervention, the treatment of donors will be 
according to normal routine. Study blood samples will be 
acquired from donors before (selected centres) and after 
the intervention.
Outcomes
The primary outcome measure is DGF of kidney 
allografts, which is defined as the need for dialysis within 
the first week after transplantation. Secondary outcome 
measures are different for different organs (box 1). 
Outcomes are assessed during the primary hospital stay, 
and thereafter at the routine follow- up visits. Helsinki 
University Hospital has a legal requirement to main-
tain a registry of all patients receiving a transplant in 
Finland, and data regarding visits in other hospitals are 
submitted to Helsinki University Hospital for registry 
purposes. Secondary outcomes are assessed directly from 
the registry, from the data provided by other hospitals, or 
at routine follow- up visits at Helsinki University Hospital. 
Survival status is automatically updated to the registry 
from the National Population Centre, which is an exact, 
complete, and up- to- date source for causes of death in 
Finland. Prespecified subgroup analyses are planned 
for characteristics that may potentially affect the results 
(table 1). Further exploratory outcome measures will 
be done according to online supplemental file 3. In the 
informed consent, the patients are also asked to give their 
permission for using the excess study blood, urine and 
tissue samples in possible ancillary analysis.
Statistical analyses
The incidence of DGF in kidney allografts after trans-
plantation from a brain- dead donor in Finland is approx-
imately 25% (Finnish Transplantation Registry). We 
aim to show that RIPC reduces the incidence of DGF to 
15%. With a 5% significance level and 80% power, 496 
kidney transplantations are required to show this differ-
ence. Sample size is not adjusted for cross- over or loss- 
of- follow up because the risk of these are considered to 
be minimal. Usually two kidneys per donor are trans-
planted. Because a portion of procured kidneys will be 
transferred to another Nordic country according to Scan-
diaTransplant rules, are untransplantable, transplanted 
in a combined organ transplantation, or transplanted to 
a recipient below 18 years old, we assume 90% of donors 
will lead to two kidney transplantations and 10% will lead 
to one kidney transplantation within the study. We set the 
final sample size to 500 kidney transplantations, for which 
approximately 260 donors are required to be randomised.
The primary outcome measure and the secondary 
outcomes for kidney transplantation will be analysed using 
generalised linear mixed models taking into account that 
kidneys from a single donor will usually be transplanted 
to two recipients included in the study. Survival analysis 
for kidney allografts and transplant recipients are done 
using Kaplan- Meier survival diagrams and the effect 
size is estimated using Cox proportional hazards regres-
sion model similarly taking into account single donor 
providing kidneys to two recipients.
The categorical outcome variables for liver, pancreas, 
heart and lungs are analysed with χ2 test (or Fischer’s 
exact test, if n is under 5 in any of the subcategories). The 
continuous outcome variables for these organs are anal-
ysed using independent t- test or Mann- Whitney U test 
depending on whether the outcome has normal distri-
bution or not. The effect size for categorical variables is 
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calculated with OR and 95% CI. For continuous variables 
the effect size is calculated with difference in means with 
95 % CI for variables with normal distribution. If a contin-
uous variable can be converted for normal distribution 
with a logarithmic transformation, will the effect size be 
reported using the ratio of geometrical means with 95% 
CI. Other continuous variables will be calculated using 
Mann- Whitney U test and the effect size will be reported 
using r=Z/√N without 95% CI. Survival analysis for these 
organs will be described using Kaplan- Meier survival 
diagrams and log- rank test and effect size estimated using 
Cox proportional hazards regression model.
Subgroup analysis will be made using generalised linear 
mixed models as univariate analysis by adjusting models 
by subgroup. A multivariate analysis of subgroups can 
be done with aforementioned generalised linear model 
and by selecting the significant subgroups (p<0.05) from 
univariate analysis as covariates. Subgroup analysis for 
survival variables will be described with Kaplan- Meier, 
which will be stratified by subgroup and effect size will 
be estimated using Cox proportional hazards regression 
model by adjusting it with the subgroup.
In case that because of missing values more than 5% 
of patients would be left out from sensitivity analyses, 
multiple imputations may be used to conduct sensitivity 
analyses. Otherwise, the missing data will not be adjusted 
separately, but these cases will either be left out from the 
analyses or censored at the last point of follow- up.
Data security
All patient data included in the study is confidential and 
will be concealed on a computer behind an Advanced 
Encryption Standard (AES) 256- bit encryption. Any data 
stored in a paper from will be held in the study hospitals 
Box 1 Secondary outcome measures
Kidney allografts
 ► Estimated glomerular filtration rate at 3 months, 1 year, 2 years, 5 
years, 10 years and 20 years.
 ► Biopsy- proven acute rejection (BPAR) within 1 year.
 ► Graft survival at 3 months, 1 year, 2 years, 5 years, 10 years and 
20 years: time from transplantation to death, retransplantation or 
permanent dialysis.
 ► Death- censored graft survival at 3 months, 1 year, 2 years, 5 years, 
10 years and 20 years: time from transplantation to retransplanta-
tion or permanent dialysis, death- censored.
Pancreatic allografts
 ► Glycosylated haemoglobin at 3 months, 1 year, 2 years, 5 years, 10 
years and 20 years.
 ► Acute rejection in pancreatic allograft, either biopsy- proven (al-
lograft pancreas or duodenal biopsy) acute rejection or clinically 
treated suspected acute rejection within 1 year.
 ► Pancreatic allograft survival at 3 months, 1 year, 2 years, 5 years, 10 
years and 20 years: time from transplantation to death, retransplan-
tation, explantation or daily insulin dependence.
 ► Death- censored pancreatic allograft survival at 3 months, 1 year, 2 
years, 5 years, 10 years and 20 years: time from transplantation to 
death, retransplantation, explantation or daily insulin dependence, 
death- censored.
Liver allografts
 ► MEAF- score at third postoperative day (POD): Model for Early 
Allograft Function Scoring. MEAF=score ALTmax:3POD+score 
INRmax: 3POD+score bilirubin3POD, score range 0–10, higher 
score indicates worse outcome.30
 ► Postoperative biliary complications within 1 year: amount and type 
of postoperative biliary complications: stricture at anastomosis, bile 
leak or ischaemic type biliary lesions (ITBL) requiring intervention 
(endoscopic retrograde cholangiography, percutaneous transhepat-
ic catheter, operation) or prolonged drainage within 1 year.
 ► Post- transplantation kidney injury (acute kidney injury) within 1 
week, at 3 months, 1 year: according to Acute Dialysis Quality 
Initiative (ADQI) 2010 criteria.31
 ► BPAR within 1 year.
 ► Graft survival at 1 year, 2 years, 5 years, 10 years and 20 years: time 
from transplantation to death, retransplantation or explantation.
Heart allografts
 ► Ischaemia- reperfusion injury determined by peripheral blood TnI 
levels at 6 hours hours after transplantation.
 ► Peripheral blood proBNP measurement at 1 week after 
transplantation.
 ► Primary graft dysfunction according to the International Society for 
Heart & Lung Transplantation (ISHLT) definition32 within 24 hours 
after transplantation.
 ► Biopsy- proven or clinically treated acute rejection within 1 year after 
transplantation.
 ► Vasculopathy- free survival according to ISHLT definition33 at 1 year, 
2 years, 5 years, 10 years and 20 years.
 ► Graft survival at 1 year, 2 years, 5 years, 10 years and 20 years, time 
from transplantation to death, retransplantation or explantation.
Lung allografts
 ► Primary graft dysfunction according to ISHLT definition34 within 72 
hours after transplantation.
 ► Biopsy proven or clinically treated acute rejection within 1 year.
 ► Chronic lung allograft dysfunction free survival according to ISHLT/
American Thoracic Society (ATS)/European Respiratory Society 
Continued
Box 1 Continued
(ERS) 2014 guideline35 at 1 year, 2 years, 5 years, 10 years and 20 
years, time from transplantation to death or retransplantation.
 ► Graft survival at 1 year, 2 years, 5 years, 10 years and 20 
years: time from transplantation to death, retransplantation or 
explantation.





Donor age (years) Under 60/over 60
Donor sex Male/female
Organ cold ischaemia time 
(hours, organ specific)
Below/above median
Uncompleted study intervention Yes/no
Liver transplantation for acute 
liver failure
Yes/no
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in locked offices. Only the study personnel will have the 
access to the trial dataset.
Schedule and interim safety analyses
The study was conceptualised in June 2017. The study 
plan was approved by the Helsinki University Hospi-
tal’s Ethics Committee 9 May 2018. Helsinki University 
Hospital’s Institutional Review Board gave permission 
to conduct the study 14 August 2018. The study started 
recruiting in 13 May 2019 in four out of five university 
hospitals in Finland. The Ethics Committee required a 
safety analysis after 16 donors had been randomised. The 
donors and recipients of kidneys from these 16 donors 
were analysed without unmasking the allocated group. All 
16 donors randomised successfully underwent procure-
ment. No adverse events were noted in the recipients. 
After this safety analysis, the study will be disseminated 
to non- university donor hospitals. Second interim analysis 
will be done when half of the target sample size is reached 
(250 kidney transplantations). In Finland, approximately 
230 DBD kidney transplants are being performed annu-
ally. We estimate that data for primary outcome would be 
available in 4 years.
Role of the funding sources and sponsors
The funders or sponsors have had and will have no role 
in study design, data collection, data analysis, data inter-
pretation, or writing the report, or any other aspect of the 
work, except for funding.
Patient and public involvement




This study has been approved by Helsinki University 
Hospital Ethics Committee and Helsinki University 
Hospital’s Institutional Review Board.
The intervention is performed on a donor, who has 
been determined brain dead and has given permission 
to act as a donor according to Finnish legislation, and is 
determined suitable and scheduled for kidney procure-
ment. The Ethics Committee has approved that donors 
(or next of kin) do not need to consent to RIPC or 
sham- procedure because it is a non- invasive procedure, 
the donor is brain dead and scheduled for procurement 
already.
The recipients of organs from randomised donors will 
be recruited in the study and will be required to give 
written informed consent to participate. The recipient 
cannot influence whether the donor has been randomised 
or received the allocated treatment. The recipient has 
the right to decline participation in the trial, but can still 
choose to receive the planned allograft. In these cases, 
the recipient’s data are not used in the study analyses. The 
recipient has also right to decline the offered organ. The 
recipient does not have the right to know the allocated 
treatment the donor has received before the study has 
been completed, data analysed and blinding unmasked. 
The donors or recipients do not receive any compensa-
tion for their participation in the trial. The recipients 
have the right to discontinue the trial or withdraw their 
consent at any point. In these cases, the collected data will 
be used in the analyses up to the point of discontinuation.
A few additional blood samples (and a urine sample 
from the kidney recipients) will be taken from the kidney, 
heart and lung recipients for the study purposes during 
and shortly after the transplantation, but otherwise the 
recipients only give their consent to the study group to 
observe and collect medical information. These samples 
are stored maximally for 5 years after the completion of 
the study recruitment. The patient informed consent 
forms are in Finnish and Swedish and will be provided by 
request made to the study group.
Harms
Earlier studies on RIPC have not indicated any harm 
(7–16). On the contrary, many earlier studies suggest that 
RIPC may be beneficial for the function and longevity of 
the allografts. Before wider adoption of the RIPC in trans-
plantation, its safety and benefits need to be addressed 
in a randomised controlled trial such as RIPTRANS. 
Any possible harmful effects of the intervention will be 
reported together with the study results. The Finnish 
patient insurance covers the organ recipients partici-
pating in the study.
Monitoring
Helsinki University Hospital Ethics Board monitored the 
results of the first interim analysis. Initially the Ethics 
board did not necessitate a separate Data Monitoring 
Committee (DMC). To provide external validity for the 
study, a DMC contract was made with Clinical Research 
Institute HUCH (HYKS Instituutti) in March 2020. 
The site monitoring will be performed every 3 months 
including review of the Investigator’s Trial File, facilities, 
the equipment at the site, compliance to study protocol 
and study specific procedures, source document quality 
and the intervention implementation documentation for 
all donors. All the study patients will be monitored for: 
existence, informed consent process and documentation 
of the trial outcome measures. A complete review will be 
conducted for 10% of the subjects. A close- out visit shall 
be done after all the data have been collected and the 
treatment of all the subjects has been completed. This 
monitoring plan and agreement is made in collaboration 
with the guideline for coordinated Good Clinical Practive 
(GCP)- monitoring of clinical trials in the Nordic coun-
tries (V.5/24 October 2017).
Dissemination
The study protocol was be presented at the European 
Society of Organ Transplantation congress in Copenhagen 
14–15 September 2019 and will possibly be presented in 
other scientific conferences. The study results will be 
submitted to an international peer- reviewed scientific 
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journal for publication and possibly discussed at scientific 
meetings. The study is also being made public via social 
media platforms (Twitter). The International Committee 
of Medical Journal Editors recommendations ( www. 
ICMJE. org) are applied when considering the authorship 
of any publications from this trial.
DISCUSSION
We formed our study protocol based on earlier RIPC 
studies. The RIPC intervention on transplant recipients 
has already been thoroughly studied by Krogstrup et al26 
and we saw more potential in performing the interven-
tion prior to organ procurement, in deceased donors. 
Our RIPC tourniquet protocol is similar to several earlier 
trials.12–14 26 Our intervention is performed on thigh 
(instead of upper extremity), which has a larger mass 
and could thus produce larger effect, and donor arms are 
usually used for cannulas which could cause interference 
with RIPC. A constant tourniquet pressure of 300 mm Hg 
was selected because it ensures that the circulation to the 
lower extremity is ceased and ischaemia introduced. Also, 
a static pressure protocol instead of changing the pres-
sure according to systolic blood pressure is simpler and 
easier to reproduce.
The aim of our study is to be able to show a decrease in 
DGF rate from 25% to 15%. The largest kidney transplant 
RIPC trial thus far, the REPAIR trial, recruited 406 kidney 
recipients and the reported a positive long- term outcome 
for kidney function, but not in DGF.28 29 A DGF difference 
in living donor setting is hard to show because of very 
low incidence of DGF compared with deceased donation. 
A DGF reduction of 10 percentage points was chosen 
because there were several reasons assume that the effect 
of RIPC would be higher in our study. First, the interven-
tion is performed on thigh with larger mass compared with 
arm as noted above. Second, intervention is performed 
on DBD donors, in which both warm and cold ischaemia 
times are longer than in living donors, where the earlier 
trials have mostly been conducted. Further, we think that 
the effect of RIPC could be larger because of the systemic 
inflammatory cascade in DBD donors, which RIPC might 
be able to alleviate. All in all, these are hypotheses, which 
are now being tested in a novel double- blind randomised 
controlled trial. An interim analysis will be made when 
half of the sample size is recruited (250 kidney trans-
plant recipients) and at that point, we will acquire a more 
precise estimate of the effect.
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